Menu Search
Equities

CARsgen Therapeutics Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2171:HKG.HS

CARsgen Therapeutics Holdings Ltd

Actions
  • Price (HKD)14.40
  • Today's Change0.40 / 2.86%
  • Shares traded747.50k
  • 1 Year change+50.79%
  • Beta1.2946
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)95.19m
  • Net income in HKD-591.11m
  • Incorporated2018
  • Employees371.00
  • Location
    CARsgen Therapeutics Holdings Ltd1F, Building 2,No. 466 Yindu Road, XuhuSHANGHAI ChinaCHN
  • Websitehttps://www.carsgen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.